PTC Therapeutics shows exceptional momentum with an RSI of 71, rising OBV, and a 2.8x average volume surge, but is constrained by cash-burning operations with free cash flow at -51% of revenue, low business quality, and an asymmetry ratio of only 0.52 that fails the minimum entry threshold.
Thesis pillars
- Price Momentum Surge↑Improving
- Cash Burn Quality Deficit↑Improving
- Earnings Improvement Trajectory↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026· older than 90 days
PTC Therapeutics, Inc. (PTCT) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $68.97, but acceptable to hold if already in. Reasons: Consecutive earnings misses (2); Below 200-MA, MA slope -2.8%/30d (confirmed downtrend).
PTC Therapeutics is a global biopharmaceutical company commercializing rare disease treatments including Sephience (PKU, FDA-approved July 2025), Emflaza and Translarna (DMD), Upstaza/Kebilidi (AADC deficiency), and Evrysdi (SMA) via a Roche collaboration. Revenue comes from... Read more
Hold if already holding. Not a fresh buy at $68.97, but acceptable to hold if already in. Reasons: Consecutive earnings misses (2); Below 200-MA, MA slope -2.8%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 65. Maintain position. Not compelling to add more. Score 6.7/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst 0.60, earnings proximity 105d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About PTC Therapeutics, Inc.
About PTC Therapeutics, Inc.
PTC Therapeutics holds marketing authorizations for six named rare disease products across neurology and metabolism: Sephience for PKU gained FDA approval in July 2025, EEA authorization in June 2025, and Japanese MHLW approval in December 2025; Emflaza is approved for DMD in the United States; Upstaza/Kebilidi for AADC deficiency received FDA accelerated approval in November 2024 and has EEA and UK authorization; Evrysdi for SMA is authorized in more than 100 countries via the Roche and SMA Foundation collaboration; and Tegsedi and Waylivra are commercialized in Latin America and the Caribbean under an Ionis collaboration.
PTC Therapeutics generates revenue through direct product sales in markets where it holds authorizations and through royalty and milestone income from collaborators. Sephience targets an estimated 58,000 patients globally living with PKU and has received authorization in the US, EEA, Japan, Brazil, and additional geographies as of the report date. The DMD franchise faces a transitional period: Emflaza's orphan drug exclusivity for patients five and older expired February 2024, triggering generic entry the company states has had a negative impact on Emflaza net product revenue, with the exclusivity period for patients two to five years old expiring June 2026. Translarna generates revenue in markets outside the EEA, but in March 2025 the European Commission adopted the CHMP's recommendation not to renew its conditional EEA marketing authorization, leaving continued EU use dependent on individual country elections under Articles 117(3) and 5(1) of EU Directive 2001/83. Evrysdi is co-commercialized with Roche, generating royalties across more than 100 countries.
Show full overview
The company's development pipeline carries overlapping regulatory setbacks within a 12-month window. Vatiquinone for Friedreich's ataxia received an FDA Complete Response Letter in August 2025 finding that substantial evidence of efficacy was not demonstrated; PTC Therapeutics plans a Q2 2026 FDA meeting to design a new open-label study with a natural history control group. The Translarna NDA resubmission for US nmDMD was withdrawn in January 2026 following negative FDA feedback. Votoplam for Huntington's disease—licensed to Novartis in November 2024—met its Phase 2 primary endpoints in May 2025 and is expected to enter a Phase 3 trial in the first half of 2026, with Novartis assuming further development responsibility.
See also: Healthcare · Biotechnology
From PTC Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Oct 29, 2026Recent Developments — PTC Therapeutics, Inc.
Latest news
- NEWS PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance — Yahoo Finance Oct 29, 2026 neutral
- NEWS PTCT Q3'26 Earnings: EPS estimate is 0.14 USD - TradingView — TradingView Oct 28, 2026 neutral
- NEWS PTC Therapeutics schedules October 29 results as stock trades below its high - ad-hoc-news.de — ad-hoc-news.de Oct 20, 2026 neutral
- NEWS PTC Therapeutics schedules October 29 results as stock trades below its high - AD HOC NEWS — AD HOC NEWS Oct 20, 2026 neutral
- NEWS PTC Therapeutics CLO Mark Boulding sells $12,337 in stock - Investing.com — Investing.com Oct 14, 2026 neutral
Latest item Oct 29, 2026 · Generated 2026-11-05T11:29:01Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductTranslarna10-K Item 1A: 'we will lose a significant portion of our ability to generate revenue from sales of Translarna in the EEA'
- MEDIUMProductEmflaza10-K Item 1: 'competition from generics, which has, and we expect will continue to have, a negative impact on Emflaza net product revenue'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02LOWPTC Therapeutics appointed Jessica Chutter to its board of directors effective March 24, 2026, filling a vacancy as a Class I director with term expiring at the 2026 annual meeting. No officer departures cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $68.97, but acceptable to hold if already in. Reasons: Consecutive earnings misses (2); Below 200-MA, MA slope -2.8%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 65. Maintain position. Not compelling to add more. Analyst target $90.42 (+31.1%), stop $64.14 (−7.5%), A.R:R 2.1:1. Score 6.7/10, moderate confidence.
Analyst target: $90.42 (+31.1% upside). Analyst target $90.42 (+31.1%), stop $64.14 (−7.5%), A.R:R 2.1:1. Stop-loss: $64.14.
Consecutive earnings misses (2); Below 200-MA, MA slope -2.8%/30d (confirmed downtrend).
PTC Therapeutics, Inc. trades at a P/E of N/A (forward 28.4). TrendMatrix value score: 6.0/10. Verdict: Hold.
21 analysts rate PTCT, with a consensus score of 4.2/5. 15 analysts publish price targets averaging $100.
What does PTC Therapeutics, Inc. do?PTC Therapeutics is a global biopharmaceutical company commercializing rare disease treatments including Sephience...
PTC Therapeutics is a global biopharmaceutical company commercializing rare disease treatments including Sephience (PKU, FDA-approved July 2025), Emflaza and Translarna (DMD), Upstaza/Kebilidi (AADC deficiency), and Evrysdi (SMA) via a Roche collaboration. Revenue comes from product sales and collaboration royalties/milestones across the US, EU, Japan, Latin America, and other markets. Emflaza faces growing generic competition following orphan exclusivity expiration in February 2024.